<DOC>
	<DOCNO>NCT00570986</DOCNO>
	<brief_summary>The purpose study determine safety efficacy 2 dose ABT-874 versus placebo treatment subject moderate severe plaque psoriasis .</brief_summary>
	<brief_title>A Study Comparing Safety Efficacy Two Dosing Regimens ABT-874 Placebo Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject &gt; = 18 year age Subject clinical diagnosis psoriasis least 6 month , moderate severe plaque psoriasis Subject judge generally good health determine principal investigator Subject previous exposure systemic antiIL 12 therapy Subject discontinue systemic therapy and/or topical therapy treatment psoriasis avoid UVB PUVA phototherapy Subject take require oral injectible corticosteroid Subject diagnose erythrodermic psoriasis , pustular psoriasis , medicationinduced medicationexacerbated psoriasis new onset guttate psoriasis Subject consider investigator , reason , unsuitable candidate Female subject pregnant breastfeeding consider become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Plaque Psoriasis</keyword>
</DOC>